Lyra Therapeutics, Inc. (NASDAQ: LYRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)